Harbour BioMed Establishes Nona Biosciences for Next-Generation Antibody Development
Harbour BioMed (HKG: 2142), a biotech company with operations in the Netherlands, the United States,...
Novartis Considers Sale of Non-Core Units to Fund Innovation
Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly considering the sale of certain ‘non-core’...
Sequanta Technologies Partners with Illumina to Introduce NovaSeq X Series
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, has entered into...
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...
MicroTech Medical Plans IPO on Shanghai’s STAR Market
China-based diabetes specialist MicroTech Medical (Hangzhou) Co., Ltd (HKG: 2235) has announced plans to conduct...
Kelun Pharma’s SKB264 Advances to Phase II Study for NSCLC
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that its antibody drug conjugate...
Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award
China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this...
Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with...
Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with...
Sirnaomics Announces Key Executive Promotions Effective November 15
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite,...
Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study
China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled,...
Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals...
Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies
Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2...
CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation
The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation...
Betta Pharmaceuticals’ BPI-D0316 Accepted for NMPA Review for NSCLC Adjuvant Therapy
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced that its clinical trial filing for...
Kelun-Biotech’s SKB264 Receives FDA Approval for Phase II Study
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd has announced receiving approval from the US FDA to...
Junovabio Secures Pre-Series A Funding for Tumor Molecular Diagnosis
Junovabio, a Shanghai-based molecular diagnostics specialist, has reportedly raised “tens of millions” of renminbi in...
Lupeng Pharma Raises USD 35 Million in Pre-Series B Financing Round
China-based Lupeng Pharmaceutical Ltd has reportedly raised USD 35 million in Phase 2 of a...
Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...
Silk Round Fund and INA Invest in Indonesian Pharma Companies
The Chinese state-owned Silk Round Fund (SRF) and Indonesia’s sovereign fund INA have reportedly agreed...